Concept information
Preferred term
Trimetrexate
Type
-
mesh:Descriptor
Definition
- A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Broader concept
Entry terms
- 117381-09-6 (monohydrate, monoacetate)
- 117381-10-9 (hydrate)
- 2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-
- 52128-35-5 (Trimetrexate)
- UPN4ITI8T4
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- agonists (Qualifier)
- analogs & derivatives (Qualifier)
- analysis (Qualifier)
- antagonists & inhibitors (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemical synthesis (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- economics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- standards (Qualifier)
- supply & distribution (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
117381-09-6 (monohydrate, monoacetate)
-
117381-10-9 (hydrate)
-
2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-
-
52128-35-5 (Trimetrexate)
-
UPN4ITI8T4
URI
http://data.loterre.fr/ark:/67375/JVR-L7C0GXDV-T
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}